{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:43:43Z","timestamp":1792035823927,"version":"4.4.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12325-025-03326-0","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T06:41:27Z","timestamp":1754462487000},"page":"4977-4992","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Glycemia Risk Index and Continuous Glucose Monitoring Outcomes Following the Transition to an Advanced Hybrid Closed-Loop System in Type 1 Diabetes"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3483-3196","authenticated-orcid":false,"given":"Ayman","family":"Al Hayek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael M.","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulghani H.","family":"Al Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak","family":"Al Mashali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Klonoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Al Dawish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"3326_CR1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","volume":"10","author":"GA Gregory","year":"2022","unstructured":"Gregory GA, Robinson TIG, Linklater SE, Wang F, Colagiuri S, de Beaufort C, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10:741\u201360.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3326_CR2","doi-asserted-by":"crossref","first-page":"9408370","DOI":"10.1155\/2018\/9408370","volume":"2018","author":"AA Robert","year":"2018","unstructured":"Robert AA, Al-Dawish A, Mujammami M, Al Dawish MA. Type 1 diabetes mellitus in Saudi Arabia: a soaring epidemic. Int J Pediatr. 2018;2018:9408370.","journal-title":"Int J Pediatr"},{"key":"3326_CR3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/POC.0000000000000125","volume":"16","author":"L Kahanovitz","year":"2017","unstructured":"Kahanovitz L, Sluss PM, Russell SJ. Type 1 diabetes \u2013 a clinical perspective. Point Care. 2017;16:37.","journal-title":"Point Care"},{"key":"3326_CR4","first-page":"477","volume-title":"Cambridge handbook of psychology health and medicine","author":"J Speight","year":"2024","unstructured":"Speight J, Pouwer F. Type 1 diabetes. In: Cambridge handbook of psychology health and medicine. 3rd ed. Cambridge University Press; 2024. p. 477\u201380.","edition":"3"},{"key":"3326_CR5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ecl.2023.09.004","volume":"53","author":"R Longendyke","year":"2024","unstructured":"Longendyke R, Grundman JB, Majidi S. Acute and chronic adverse outcomes of type 1 diabetes. Endocrinol Metab Clin North Am. 2024;53:123\u201333.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"3326_CR6","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc24-S006","volume":"47","author":"ADAPP Committee","year":"2024","unstructured":"Committee ADAPP, ElSayed NA, Aleppo G, Bannuru RR, Bruemmer D, Collins BS, et al. 6. Glycemic goals and hypoglycemia: standards of care in diabetes\u20142024. Diabetes Care. 2024;47:S111-25. https:\/\/doi.org\/10.2337\/dc24-S006.","journal-title":"Diabetes Care"},{"key":"3326_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41387-024-00319-w","volume":"14","author":"FA Mazzotta","year":"2024","unstructured":"Mazzotta FA, Lucaccini Paoli L, Rizzi A, Tartaglione L, Leo ML, Popolla V, et al. Unmet needs in the treatment of type 1 diabetes: why is it so difficult to achieve an improvement in metabolic control? Nutr Diabetes. 2024;14:1\u20137.","journal-title":"Nutr Diabetes"},{"key":"3326_CR8","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.3390\/jcm13195669","volume":"13","author":"S Azar","year":"2024","unstructured":"Azar S, Maroun Abou Jaoude N, K\u0119dzia A, Niechcia\u0142 E. Barriers to type 1 diabetes adherence in adolescents. J Clin Med. 2024;13:5669.","journal-title":"J Clin Med"},{"key":"3326_CR9","unstructured":"Subramanian S, Baidal D, Skyler JS, Hirsch IB. The Management of Type 1 Diabetes. (2021) Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279114\/"},{"key":"3326_CR10","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2337\/dc23-1765","volume":"47","author":"JL Sherr","year":"2024","unstructured":"Sherr JL, Laffel LM, Liu J, Wolf W, Bispham J, Chapman KS, et al. Severe hypoglycemia and impaired awareness of hypoglycemia persist in people with type 1 diabetes despite use of diabetes technology: results from a cross-sectional survey. Diabetes Care. 2024;47:941\u20137.","journal-title":"Diabetes Care"},{"key":"3326_CR11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40359-020-00468-4","volume":"8","author":"SE Coleman","year":"2020","unstructured":"Coleman SE, Caswell N. Diabetes and eating disorders: an exploration of \u2018Diabulimia.\u2019 BMC Psychol. 2020;8:101.","journal-title":"BMC Psychol"},{"key":"3326_CR12","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1177\/1932296820918894","volume":"15","author":"RS Rigo","year":"2020","unstructured":"Rigo RS, Levin LE, Belsito DV, Garzon MC, Gandica R, Williams KM. Cutaneous reactions to continuous glucose monitoring and continuous subcutaneous insulin infusion devices in type 1 diabetes mellitus. J Diabetes Sci Technol. 2020;15:786.","journal-title":"J Diabetes Sci Technol"},{"key":"3326_CR13","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.4239\/wjd.v12.i12.2036","volume":"12","author":"A Nakhleh","year":"2021","unstructured":"Nakhleh A, Shehadeh N. Hypoglycemia in diabetes: an update on pathophysiology, treatment, and prevention. World J Diabetes. 2021;12:2036.","journal-title":"World J Diabetes"},{"key":"3326_CR14","unstructured":"Ward CW, Lawrence MC. Insulin- pharmacology, therapeutic regimens and principles of intensive insulin therapy. Front Endocrinol (Lausanne) (2000) pp. 2. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25905175\/"},{"key":"3326_CR15","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1007\/s00125-021-05568-3","volume":"64","author":"RIG Holt","year":"2021","unstructured":"Holt RIG, DeVries JH, Hess-Fischl A, Hirsch IB, Kirkman MS, Klupa T, et al. The management of type 1 diabetes in adults. a consensus report by the American diabetes association (ada) and the European association for the study of diabetes (EASD). Diabetologia. 2021;64:2609.","journal-title":"Diabetologia"},{"key":"3326_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2337\/dc24-1474","volume":"48","author":"LM Laffel","year":"2025","unstructured":"Laffel LM, Sherr JL, Liu J, Wolf WA, Bispham J, Chapman KS, et al. Limitations in achieving glycemic targets from CGM data and persistence of severe hypoglycemia in adults with type 1 diabetes regardless of insulin delivery method. Diabetes Care. 2025;48:273\u20138. https:\/\/doi.org\/10.2337\/dc24-1474.","journal-title":"Diabetes Care"},{"key":"3326_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s13300-023-01486-2","volume":"15","author":"A Chico","year":"2024","unstructured":"Chico A, Moreno-Fern\u00e1ndez J, Fern\u00e1ndez-Garc\u00eda D, Sol\u00e1 E. The hybrid closed-loop system tandem t:slim X2TM with control-IQ technology: expert recommendations for better management and optimization. Diabetes Ther. 2024;15:281\u201395. https:\/\/doi.org\/10.1007\/s13300-023-01486-2.","journal-title":"Diabetes Ther"},{"key":"3326_CR18","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1056\/NEJMoa1907863","volume":"381","author":"SA Brown","year":"2019","unstructured":"Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. New England J Med. 2019;381:1707\u201317.","journal-title":"New England J Med"},{"key":"3326_CR19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/dia.2022.0558","volume":"25","author":"RW Beck","year":"2023","unstructured":"Beck RW, Kanapka LG, Breton MD, Brown SA, Wadwa RP, Buckingham BA, et al. A meta-analysis of randomized trial outcomes for the t:slim X2 insulin pump with control-IQ technology in youth and adults from age 2 to 72. Diabetes Technol Ther. 2023;25:329\u201342.","journal-title":"Diabetes Technol Ther"},{"key":"3326_CR20","doi-asserted-by":"crossref","first-page":"e3842","DOI":"10.1002\/dmrr.3842","volume":"40","author":"S Di Molfetta","year":"2024","unstructured":"Di Molfetta S, Di Gioia L, Caruso I, Cignarelli A, Green SC, Natale P, et al. Efficacy and safety of different hybrid closed loop systems for automated insulin delivery in people with type 1 diabetes: a systematic review and network meta-analysis. Diabetes Metab Res Rev. 2024;40:e3842.","journal-title":"Diabetes Metab Res Rev"},{"key":"3326_CR21","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1089\/dia.2023.0040","volume":"25","author":"C Piona","year":"2023","unstructured":"Piona C, Marigliano M, Roncar\u00e0 C, Mozzillo E, Di Candia F, Zanfardino A, et al. Glycemia risk index as a novel metric to evaluate the safety of glycemic control in children and adolescents with type 1 diabetes: an observational, multicenter real-life cohort study. Diabetes Technol Ther. 2023;25:507\u201312.","journal-title":"Diabetes Technol Ther"},{"issue":"465","key":"3326_CR22","first-page":"71","volume":"68","author":"G D\u00edaz-Soto","year":"2021","unstructured":"D\u00edaz-Soto G, Bah\u00edllo-Curieses MP, Jimenez R, Nieto MDLO, Gomez E, Torres B, et al. The relationship between glycosylated hemoglobin, time-in-range and glycemic variability in type 1 diabetes patients under flash glucose monitoring. Endocrinol Diabetes y Nutr (English ed). 2021;68(465):71.","journal-title":"Endocrinol Diabetes y Nutr (English ed)"},{"key":"3326_CR23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40200-025-01569-w","volume":"24","author":"A Al Hayek","year":"2025","unstructured":"Al Hayek A, Al Mashali M, Al Dawish MA. Evaluation of glycemia risk index and continuous glucose monitoring-derived metrics in type 1 diabetes: a real-world observational study. J Diabetes Metab Disord. 2025;24:59.","journal-title":"J Diabetes Metab Disord"},{"key":"3326_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/19322968241301750","author":"A Al Hayek","year":"2024","unstructured":"Al Hayek A, Al Dawish MA. Improvement of glycemia risk index and continuous glucose monitoring metrics during ramadan fasting in type 1 diabetes: a real-world observational study. J Diabetes Sci Technol. 2024. https:\/\/doi.org\/10.1177\/19322968241301750.","journal-title":"J Diabetes Sci Technol"},{"key":"3326_CR25","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/19322968241247215","volume":"18","author":"K Panfil","year":"2024","unstructured":"Panfil K, Vandervelden CA, Lockee B, Tallon EM, Williams DD, Lee JM. The glycemia risk index predicts performance of diabetes self-management habits in youth with type 1 diabetes mellitus. J Diabetes Sci Technol. 2024;18:779\u201386.","journal-title":"J Diabetes Sci Technol"},{"key":"3326_CR26","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1177\/19322968221085273","volume":"17","author":"DC Klonoff","year":"2023","unstructured":"Klonoff DC, Wang J, Rodbard D, Kohn MA, Li C, Liepmann D, et al. A glycemia risk index (GRI) of hypoglycemia and hyperglycemia for continuous glucose monitoring validated by clinician ratings. J Diabetes Sci Technol. 2023;17:1226\u201342.","journal-title":"J Diabetes Sci Technol"},{"key":"3326_CR27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/dia.2023.0565","volume":"26","author":"TC Dunn","year":"2024","unstructured":"Dunn TC, Ajjan RA, Bergenstal RM, Xu Y. Is it time to move beyond TIR to TITR? real-world data from over 20,000 users of continuous glucose monitoring in patients with type 1 and type 2 diabetes. Diabetes Technol Ther. 2024;26:203.","journal-title":"Diabetes Technol Ther"},{"key":"3326_CR28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/dia.2023.0373","volume":"26","author":"S Passanisi","year":"2024","unstructured":"Passanisi S, Piona C, Salzano G, Marigliano M, Bombaci B, Morandi A, et al. Aiming for the best glycemic control beyond time in range: time in tight range as a new continuous glucose monitoring metric in children and adolescents with type 1 diabetes using different treatment modalities. Diabetes Technol Ther. 2024;26:161\u20136.","journal-title":"Diabetes Technol Ther"},{"key":"3326_CR29","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","volume":"12","author":"E von Elm","year":"2014","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12:1495\u20139.","journal-title":"Int J Surg"},{"key":"3326_CR30","first-page":"373","volume":"79","author":"JAVA","year":"2013","unstructured":"JAVA. Declaration of Helsinki world medical association declaration of Helsinki. Bull World Health Organ. 2013;79:373\u20134.","journal-title":"Bull World Health Organ"},{"key":"3326_CR31","doi-asserted-by":"crossref","first-page":"e22212","DOI":"10.2196\/22212","volume":"8","author":"AK B\u00f6hm","year":"2020","unstructured":"B\u00f6hm AK, Jensen ML, S\u00f8rensen MR, Stargardt T. Real-world evidence of user engagement with mobile health for diabetes management: longitudinal observational study. JMIR Mhealth Uhealth. 2020;8:e22212.","journal-title":"JMIR Mhealth Uhealth"},{"key":"3326_CR32","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s12020-023-03511-7","volume":"82","author":"P P\u00e9rez-L\u00f3pez","year":"2023","unstructured":"P\u00e9rez-L\u00f3pez P, F\u00e9rnandez-Velasco P, Bahillo-Curieses P, de Luis D, D\u00edaz-Soto G. Impact of glucose variability on the assessment of the glycemia risk index (GRI) and classic glycemic metrics. Endocrine. 2023;82:560\u20138.","journal-title":"Endocrine"},{"key":"3326_CR33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2019.03.014","volume":"63","author":"L Barski","year":"2019","unstructured":"Barski L, Eshkoli T, Brandstaetter E, Jotkowitz A. Euglycemic diabetic ketoacidosis. Eur J Intern Med. 2019;63:9\u201314.","journal-title":"Eur J Intern Med"},{"key":"3326_CR34","doi-asserted-by":"crossref","first-page":"1243565","DOI":"10.3389\/fendo.2024.1243565","volume":"15","author":"V Castorani","year":"2024","unstructured":"Castorani V, Rigamonti A, Frontino G, Morotti E, Sandullo F, Scialabba F, et al. Turning the tides: achieving rapid and safe glucose control in adolescents with suboptimally controlled type 1 diabetes using advanced hybrid closed loop systems. Front Endocrinol (Lausanne). 2024;15:1243565.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3326_CR35","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1007\/s00125-025-06366-x","volume":"68","author":"J De Meulemeester","year":"2025","unstructured":"De Meulemeester J, Keymeulen B, De Block C, Van Huffel L, Taes Y, Ballaux D, et al. One-year real-world benefits of tandem control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study. Diabetologia. 2025;68:948\u201360. https:\/\/doi.org\/10.1007\/s00125-025-06366-x.","journal-title":"Diabetologia"},{"key":"3326_CR36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1089\/dia.2023.0341","volume":"26","author":"R Graham","year":"2024","unstructured":"Graham R, Mueller L, Manning M, Habif S, Messer LH, Pinsker JE, et al. Real-world use of control-IQ technology is associated with a lower rate of severe hypoglycemia and diabetic ketoacidosis than historical data: results of the control-IQ observational (CLIO) prospective study. Diabetes Technol Ther. 2024;26:24\u201332.","journal-title":"Diabetes Technol Ther"},{"key":"3326_CR37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/dia.2024.0501","volume":"27","author":"SA Brown","year":"2024","unstructured":"Brown SA, Laffel LM, Akturk HK, Forlenza GP, Shah VN, Wadwa RP, et al. Randomized, crossover trial of control-IQ technology with a lower treatment range and a modified meal bolus module in adults, adolescents, children, and preschoolers with varying levels of baseline glycemic control. Diabetes Technol Ther. 2024;27:187\u201393.","journal-title":"Diabetes Technol Ther"},{"key":"3326_CR38","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1159\/000521430","volume":"94","author":"C Piona","year":"2021","unstructured":"Piona C, Marigliano M, Mozzillo E, Di Candia F, Zanfardino A, Iafusco D, et al. High glycemic variability is associated with worse continuous glucose monitoring metrics in children and adolescents with type 1 diabetes. Horm Res Paediatr. 2021;94:369\u201373. https:\/\/doi.org\/10.1159\/000521430.","journal-title":"Horm Res Paediatr"},{"key":"3326_CR39","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1089\/dia.2019.0075","volume":"21","author":"AM G\u00f3mez","year":"2019","unstructured":"G\u00f3mez AM, Henao DC, Imitola Madero A, Taboada LB, Cruz V, Robledo G\u00f3mez MA, et al. Defining high glycemic variability in type 1 diabetes: comparison of multiple indexes to identify patients at risk of hypoglycemia. Diabetes Technol Ther. 2019;21:430\u20139.","journal-title":"Diabetes Technol Ther"},{"key":"3326_CR40","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1111\/jdi.14303","volume":"15","author":"T Urakami","year":"2024","unstructured":"Urakami T, Terada H, Tanabe S, Mine Y, Aoki M, Aoki R, et al. Clinical significance of coefficient of variation in continuous glucose monitoring for glycemic management in children and adolescents with type 1 diabetes. J Diabetes Investig. 2024;15:1669\u201374. https:\/\/doi.org\/10.1111\/jdi.14303.","journal-title":"J Diabetes Investig"},{"key":"3326_CR41","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s40001-024-01946-w","volume":"29","author":"E Resmini","year":"2024","unstructured":"Resmini E, Zarra E, Dotti S, Rotondi G, Cornaghi AV, Madaschi S, et al. Impact on glycemia risk index and other metrics in type 1 adult patients switching to advanced hybrid closed-loop systems: a one-year real-life experience. Eur J Med Res. 2024;29:365.","journal-title":"Eur J Med Res"},{"key":"3326_CR42","doi-asserted-by":"crossref","first-page":"101617","DOI":"10.1016\/j.diabet.2025.101617","volume":"51","author":"S Picard","year":"2025","unstructured":"Picard S, Courbebaisse B, Dupont J, Amiot-Chapoutot F, Lecornet-Sokol E, Personeni E, et al. Glycemia Risk Index (GRI) and international glucose targets before and 6 months after initiation of hybrid closed loop system in the CIRDIA, a French multisite out-of-hospital center. Diabetes Metab. 2025;51:101617.","journal-title":"Diabetes Metab"},{"key":"3326_CR43","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.2337\/dc23-0685","volume":"46","author":"E Renard","year":"2023","unstructured":"Renard E, Joubert M, Villard O, Dreves B, Reznik Y, Farret A, et al. Safety and efficacy of sustained automated insulin delivery compared with sensor and pump therapy in adults with type 1 diabetes at high risk for hypoglycemia: a randomized controlled trial. Diabetes Care. 2023;46:2180\u20137.","journal-title":"Diabetes Care"},{"key":"3326_CR44","doi-asserted-by":"publisher","DOI":"10.1177\/19322968241234072","author":"AL Carlson","year":"2024","unstructured":"Carlson AL, Graham TE, Akturk HK, Liljenquist DR, Bergenstal RM, Sulik B, et al. Control-IQ technology use in individuals with high insulin requirements: results from the multicenter higher-IQ trial. J Diabetes Sci Technol. 2024. https:\/\/doi.org\/10.1177\/19322968241234072.","journal-title":"J Diabetes Sci Technol"},{"key":"3326_CR45","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1089\/dia.2024.0048","volume":"26","author":"CJ Levy","year":"2024","unstructured":"Levy CJ, Bailey R, Laffel LM, Forlenza G, DiMeglio LA, Hughes MS, et al. Multicenter evaluation of ultra-rapid lispro insulin with control-IQ technology in adults, adolescents, and children with type 1 diabetes. Diabetes Technol Ther. 2024;26:652\u201360.","journal-title":"Diabetes Technol Ther"},{"key":"3326_CR46","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/dom.14605","volume":"24","author":"E Renard","year":"2022","unstructured":"Renard E, Tubiana-Rufi N, Bonnemaison E, Coutant R, Dalla-Vale F, Bismuth E, et al. Outcomes of hybrid closed-loop insulin delivery activated 24\/7 versus evening and night in free-living prepubertal children with type 1 diabetes: a multicentre, randomized clinical trial. Diabetes Obes Metab. 2022;24:511\u201321.","journal-title":"Diabetes Obes Metab"},{"key":"3326_CR47","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2337\/dc20-1729","volume":"44","author":"LG Kanapka","year":"2021","unstructured":"Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, Forlenza GP, et al. Extended use of the control-iq closed-loop control system in children with type 1 diabetes. Diabetes Care. 2021;44:473\u20138.","journal-title":"Diabetes Care"},{"key":"3326_CR48","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1111\/dom.14491","volume":"23","author":"V Cherubini","year":"2021","unstructured":"Cherubini V, Rabbone I, Berioli MG, Giorda S, Lo Presti D, Maltoni G, et al. Effectiveness of a closed-loop control system and a virtual educational camp for children and adolescents with type 1 diabetes: a prospective, multicentre, real-life study. Diabetes Obes Metab. 2021;23:2484\u201391.","journal-title":"Diabetes Obes Metab"},{"key":"3326_CR49","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2337\/dc23-1355","volume":"47","author":"PI Beato-V\u00edbora","year":"2024","unstructured":"Beato-V\u00edbora PI, Chico A, Moreno-Fernandez J, Bellido-Casta\u00f1eda V, Nattero-Ch\u00e1vez L, Pic\u00f3n-C\u00e9sar MJ, et al. A multicenter prospective evaluation of the benefits of two advanced hybrid closed-loop systems in glucose control and patient-reported outcomes in a real-world setting. Diabetes Care. 2024;47:216\u201324.","journal-title":"Diabetes Care"},{"key":"3326_CR50","doi-asserted-by":"crossref","first-page":"112070","DOI":"10.1016\/j.diabres.2025.112070","volume":"222","author":"PI Beato-V\u00edbora","year":"2025","unstructured":"Beato-V\u00edbora PI, Chico A, Moreno-Fernandez J, Azriel-Mira S, Nattero-Ch\u00e1vez L, Mora RV, et al. Transitioning between automated insulin delivery systems: a focus on personalisation. Diabetes Res Clin Pract. 2025;222:112070.","journal-title":"Diabetes Res Clin Pract"},{"key":"3326_CR51","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/dom.15344","volume":"26","author":"Z Henry","year":"2024","unstructured":"Henry Z, Villar Fimbel S, Bendelac N, Perge K, Thivolet C. Beneficial effects of automated insulin delivery over one-year follow-up in real life for youths and adults with type 1 diabetes irrespective of patient characteristics. Diabetes Obes Metab. 2024;26:557\u201366.","journal-title":"Diabetes Obes Metab"},{"key":"3326_CR52","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1111\/dom.15766","volume":"26","author":"A Rizzi","year":"2024","unstructured":"Rizzi A, Tartaglione L, Lucaccini Paoli L, Leo ML, Popolla V, Viti L, et al. Evaluation of time in tight range and the glycaemia risk index in adults with type 1 diabetes using an advanced hybrid closed loop system: a 1-year real-world assessment. Diabetes Obes Metab. 2024;26:4078\u201386.","journal-title":"Diabetes Obes Metab"},{"key":"3326_CR53","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/s13300-024-01618-2","volume":"15","author":"C Mameli","year":"2024","unstructured":"Mameli C, Smylie GM, Marigliano M, Zagaroli L, Mancioppi V, Maffeis C, et al. Safety and psychological outcomes of tandem t: Slim X2 insulin pump with control-IQ Technology in children, adolescents, and young adults with type 1 diabetes: a systematic review. Diabetes Ther. 2024;15:2133\u201349. https:\/\/doi.org\/10.1007\/s13300-024-01618-2.","journal-title":"Diabetes Ther"},{"key":"3326_CR54","doi-asserted-by":"crossref","first-page":"15015","DOI":"10.1111\/dme.15015","volume":"40","author":"SM Ng","year":"2023","unstructured":"Ng SM, Wright NP, Yardley D, Campbell F, Randell T, Trevelyan N, et al. Real world use of hybrid-closed loop in children and young people with type 1 diabetes mellitus\u2014a national health service pilot initiative in England. Diabetic Med. 2023;40:15015.","journal-title":"Diabetic Med"},{"key":"3326_CR55","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2337\/dc21-1778","volume":"45","author":"EC Cobry","year":"2022","unstructured":"Cobry EC, Bisio A, Paul Wadwa R, Breton MD. Improvements in parental sleep, fear of hypoglycemia, and diabetes distress with use of an advanced hybrid closed-loop system. Diabetes Care. 2022;45:1292\u20135.","journal-title":"Diabetes Care"},{"key":"3326_CR56","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/dia.2020.0532","volume":"23","author":"EC Cobry","year":"2021","unstructured":"Cobry EC, Kanapka LG, Cengiz E, Carria L, Ekhlaspour L, Buckingham BA, et al. Health-related quality of life and treatment satisfaction in parents and children with type 1 diabetes using closed-loop control. Diabetes Technol Ther. 2021;23:401\u20139.","journal-title":"Diabetes Technol Ther"},{"key":"3326_CR57","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/dia.2023.0450","volume":"26","author":"BE Marks","year":"2024","unstructured":"Marks BE, Grundman JB, Meighan S, Monaghan M, Streisand R, Perkins A. Hybrid closed loop systems improve glycemic control and quality of life in historically minoritized youth with diabetes. Diabetes Technol Ther. 2024;26:167\u201375.","journal-title":"Diabetes Technol Ther"},{"key":"3326_CR58","doi-asserted-by":"crossref","first-page":"70043","DOI":"10.1002\/edm2.70043","volume":"8","author":"S Fisker","year":"2025","unstructured":"Fisker S, Christensen M, Bach E, Bibby BM, Hansen KW. Long-term performance of two systems for automated insulin delivery in adults with type 1 diabetes: an observational study. Endocrinol Diabetes Metab. 2025;8:70043.","journal-title":"Endocrinol Diabetes Metab"},{"key":"3326_CR59","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/dia.2021.0542","volume":"24","author":"J Garcia-Tirado","year":"2022","unstructured":"Garcia-Tirado J, Farhy L, Nass R, Kollar L, Clancy-Oliveri M, Basu R, et al. Automated insulin delivery with SGLT2i combination therapy in type 1 diabetes. Diabetes Technol Ther. 2022;24:461\u201370.","journal-title":"Diabetes Technol Ther"},{"key":"3326_CR60","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/dia.2024.0022","volume":"26","author":"C Laugesen","year":"2024","unstructured":"Laugesen C, Ritschel T, Ranjan AG, Hsu L, J\u00f8rgensen JB, Svensson J, et al. Impact of missed and late meal boluses on glycemic outcomes in automated insulin delivery-treated children and adolescents with type 1 diabetes: a two-center, population-based cohort study. Diabetes Technol Ther. 2024;26:897\u2013907.","journal-title":"Diabetes Technol Ther"},{"key":"3326_CR61","doi-asserted-by":"publisher","first-page":"S146","DOI":"10.2337\/dc25-S007","volume":"48","author":"NA ElSayed","year":"2025","unstructured":"ADAPP Committee, ElSayed NA, McCoy RG, Aleppo G, Balapattabi K, Beverly EA, et al. 7 Diabetes technology: standards of care in diabetes\u20142025. Diabetes Care. 2025;48:S146-66. https:\/\/doi.org\/10.2337\/dc25-S007.","journal-title":"Diabetes Care"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03326-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03326-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03326-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:09:34Z","timestamp":1758899374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03326-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3326"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03326-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"David C Klonoff serves as a consultant to Afon, embecta, Glucotrack, Lifecare, No-vo, SynchNeuro, and Thirdwayv. The other authors, Ayman Al Hayek, Wael M. Alzahrani, Abdulghani H. Al Saeed, Malak Al Mashali and Mohamed A. Al Dawish,  declare that they have no conflicts of interest related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study was performed in line with the principles of the Declaration of Helsinki. Ethics approval was obtained from our Ethics Committee (no. 1345), which waived the need for informed consent because of the observational nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}